Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $210.43, for a total value of $4,208,600.00. Following the completion of the sale, the director now directly owns 539,176 shares in the company, valued at approximately $113,458,805.68. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of Illumina, Inc. (ILMN) traded down $0.67 during trading hours on Friday, hitting $208.94. The company’s stock had a trading volume of 598,500 shares, compared to its average volume of 970,485. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $214.50. The firm has a market capitalization of $30,603.06, a PE ratio of 61.29, a P/E/G ratio of 3.46 and a beta of 0.74. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same quarter in the previous year, the firm earned $0.97 earnings per share. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. equities analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Illumina, Inc. (ILMN) Director Sells $4,208,600.00 in Stock” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/11/illumina-inc-ilmn-director-jay-t-flatley-sells-20000-shares.html.
Large investors have recently made changes to their positions in the business. Dupont Capital Management Corp acquired a new stake in shares of Illumina in the third quarter worth about $153,000. Advisory Services Network LLC lifted its position in shares of Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after buying an additional 89 shares during the last quarter. Penserra Capital Management LLC lifted its position in shares of Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC lifted its position in shares of Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the last quarter. Finally, Patten Group Inc. lifted its position in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the last quarter. 93.07% of the stock is owned by institutional investors.
ILMN has been the topic of several recent analyst reports. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Citigroup Inc. lifted their target price on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research note on Wednesday, October 25th. Barclays PLC lifted their target price on Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 25th. Bank of America Corporation lifted their target price on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research note on Wednesday, October 25th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $205.00 target price (up previously from $200.00) on shares of Illumina in a research note on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company. Illumina presently has an average rating of “Hold” and a consensus price target of $200.88.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.